Clinical Trials Logo

Neuromyelitis Optica clinical trials

View clinical trials related to Neuromyelitis Optica.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04614454 Active, not recruiting - Clinical trials for Neuromyelitis Optica

High Frequency Impulse Therapy for Neuropathic Pain in NMOSD

Start date: June 7, 2021
Phase: Phase 2
Study type: Interventional

The aim of this study is to determine whether self-administered, at-home use of a transcutaneous electrical nerve stimulating device is an effective, acceptable and feasible method of relief from neuropathic pain among patients with Neuromyelitis optica spectrum disorder (NMOSD).

NCT ID: NCT04201262 Active, not recruiting - Clinical trials for Neuromyelitis Optica

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Start date: December 13, 2019
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to evaluate the efficacy and safety of ravulizumab for the treatment of adult participants with NMOSD.

NCT ID: NCT00716066 Active, not recruiting - Myasthenia Gravis Clinical Trials

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Start date: June 2008
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurological diseases, the patient's own immune system 'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a stem cell transplant weakens the immune system and may help stop the immune system from 'attacking' a patient's nervous system. When the patient's own (autologous) stem cells are infused into the patient they help the bone marrow make red blood cells, white blood cells, and platelets so the blood counts can improve.

NCT ID: NCT00445367 Active, not recruiting - Multiple Sclerosis Clinical Trials

Biobank For MS And Other Demyelinating Diseases

Start date: May 2006
Phase:
Study type: Observational

To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls. Samples and data will be available as a shared resource to scientists researching the causes, sub-types, and biomarkers of MS and related demyelinating diseases.

NCT ID: NCT00004645 Active, not recruiting - Clinical trials for Acute Disseminated Encephalomyelitis

Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone

Start date: January 1995
Phase: Phase 3
Study type: Interventional

OBJECTIVES: I. Evaluate the effectiveness of plasma exchange in the treatment of acute severe attacks of inflammatory demyelinating disease in patients who have failed intravenous steroid therapy.